

# MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M1682B739FBEN.html>

Date: June 2020

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: M1682B739FBEN

## Abstracts

MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for the treatment of serious and rare cardiovascular diseases including heritable cardiomyopathies. Its lead drug product candidate, mavacamten, is intended for the treatment of hypertrophic cardiomyopathy (HCM). Its other pipeline product candidates include danicamtiv (formerly MYK-491) is being developed for treating genetic dilated cardiomyopathy (DCM) and systolic heart failure; MYK-224, a small molecule for treating HCM; ACT-1 for systolic heart failure, and LUS-1, for treating diastolic heart failure. The company collaborates with healthcare organizations for the development and commercialization of its pipeline products. MyoKardia is headquartered in Brisbane, California, the US.

### MyoKardia Inc Key Recent Developments

May 06,2020: MyoKardia reports first quarter 2020 financial results

Feb 27,2020: MyoKardia reports fourth quarter and full year 2019 financial results

Nov 04,2019: MyoKardia reports third quarter 2019 financial results

Aug 15,2019: MyoKardia launches 2nd Annual MyoSeeds research grants program to advance independent research in heart disease

Aug 15,2019: MyoKardia Launches 2nd Annual MyoSeeds Research Grants Program

to Advance Independent Research in Heart Disease

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

MyoKardia Inc - Key Facts  
MyoKardia Inc - Key Employees  
MyoKardia Inc - Key Employee Biographies  
MyoKardia Inc - Major Products and Services  
MyoKardia Inc - History  
MyoKardia Inc - Company Statement  
MyoKardia Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
MyoKardia Inc - Business Description  
MyoKardia Inc - Corporate Strategy  
MyoKardia Inc - SWOT Analysis  
SWOT Analysis - Overview  
MyoKardia Inc - Strengths  
MyoKardia Inc - Weaknesses  
MyoKardia Inc - Opportunities  
MyoKardia Inc - Threats  
MyoKardia Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES**

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020  
MyoKardia Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

May 06, 2020: MyoKardia reports first quarter 2020 financial results

Feb 27, 2020: MyoKardia reports fourth quarter and full year 2019 financial results

Nov 04, 2019: MyoKardia reports third quarter 2019 financial results

Aug 15, 2019: MyoKardia launches 2nd Annual MyoSeeds research grants program to advance independent research in heart disease

Aug 15, 2019: MyoKardia Launches 2nd Annual MyoSeeds Research Grants Program to Advance Independent Research in Heart Disease

May 09, 2019: MyoKardia reports first quarter 2019 financial results

May 07, 2019: MyoKardia announces inaugural MyoSeeds Research Grants Program awardees

Feb 28, 2019: MyoKardia reports fourth quarter and full year 2018 financial results

Jan 23, 2019: MyoKardia names William Fairey as Chief Commercial Officer

Jan 03, 2019: Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

MyoKardia Inc, Key Facts  
MyoKardia Inc, Key Employees  
MyoKardia Inc, Key Employee Biographies  
MyoKardia Inc, Major Products and Services  
MyoKardia Inc, History  
MyoKardia Inc, Subsidiaries  
MyoKardia Inc, Key Competitors  
MyoKardia Inc, Ratios based on current share price  
MyoKardia Inc, Annual Ratios  
MyoKardia Inc, Annual Ratios (Cont...1)  
MyoKardia Inc, Interim Ratios  
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020  
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020  
MyoKardia Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

MyoKardia Inc, Performance Chart (2015 - 2019)

MyoKardia Inc, Ratio Charts

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

### COMPANIES MENTIONED

Amgen Inc

Takeda Pharmaceuticals America Inc

Bristol-Myers Squibb Co

Zensun (Shanghai) Sci & Tech Co Ltd

Novartis Corp

Bayer AG



## I would like to order

Product name: MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M1682B739FBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1682B739FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970